ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BYOT Byotrol Plc

0.40
-0.025 (-5.88%)
18 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -5.88% 0.40 0.35 0.45 0.425 0.40 0.43 665,718 14:40:44
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 4.59M -1.69M -0.0037 -1.08 1.82M
Byotrol Plc is listed in the Chemicals & Chem Preps sector of the London Stock Exchange with ticker BYOT. The last closing price for Byotrol was 0.43p. Over the last year, Byotrol shares have traded in a share price range of 0.40p to 2.60p.

Byotrol currently has 453,890,405 shares in issue. The market capitalisation of Byotrol is £1.82 million. Byotrol has a price to earnings ratio (PE ratio) of -1.08.

Byotrol Share Discussion Threads

Showing 7676 to 7697 of 16050 messages
Chat Pages: Latest  318  317  316  315  314  313  312  311  310  309  308  307  Older
DateSubjectAuthorDiscuss
02/2/2020
17:42
Hope they have the capacity to ramp up production!
saint in exile
02/2/2020
17:17
hxxps://www.target.com/p/byotrol24-hawaiian-sunrise-citrus-disinfectant-cleaner-plus-24-hour-surface-sanitizer-25-fl-oz/-/A-76150264 Sold out in every single target store across the united states - use link then on right go to check store availabity then press showing in stock stores only - 'the item isn't available at any store right now' - target is twice as big as tesco and has many more shops - more byotrol24 needed. Hope byotrol can meet surge in demand - 5 star rating out of 5 on customer reviews in usa. Also exceptionally bullish on swingbot: hxxps://lse.swingtradebot.com/equities/BYOT:LSE - share price low 1.6p - high 82p - currently 2.25p right product at right time. Hopefully my orders get filled at 8am.
pakenham
02/2/2020
15:23
Do we have any realistic rev forecasts?
a.fewbob
02/2/2020
15:22
1gw,

Wow, fantastic post!

a.fewbob
02/2/2020
15:02
Your latest posting strikes me as a very good resume 1gw.

Thanks.

mudbath
02/2/2020
14:53
Keep up at the back, sikhthetech. Where do you think the funds to buy Medimark came from? As I understand it, Byotrol looked at recruiting their own sales staff but came to the conclusion that a better solution was to buy Medimark which came with proven sales & marketing expertise. As you will know from following the Totally plc / Greenbrook Healthcare story, acquisitions often take longer to bring to conclusion than you might think. The earn-out mechanism caused them to silo Medimark for [edit] over 1 year post-acquisition, which must have been frustrating, but perhaps better than what happened with Totally plc where it appears the company fell out with sellers of at least one business over measurement of earn-out, presumably because they integrated too quickly and didn't silo sufficiently.

In terms of bigger picture timing, I think they've spent several years focusing mainly on the science and the regulation: getting formulae perfected and then getting formulae and labelling through the various regulatory bodies in the EU and the US. Not much good having a big sales and marketing team if you're still developing the product and labelling. I think the EU target may still be moving to some extent, but they're now in good shape on the regulatory side, especially in the US with receipt of the necessary approvals to allow them to launch byotrol 24 on a trial basis through Target.

Ultimately I view byotrol as a technology company which happens to have an FMCG market, rather than as a wholesaler or retailer. As such it has historically focused on development of the product rather than on the sales and marketing, realising a lot of its "revenue" to this point through sales or licensing of its technology/product.

The hope now, is that with product developed and sales & marketing in place, at least on the professional side, it can now ride a wave of industry change (regulatory-driven as older technologies, including possibly alcohol-based products, come under pressure). Companies such as SC Johnson (with whom byotrol have already agreed the licensing deal into the NHS), Purrell and lots of smaller ones may well be looking to license technology that already has the regulatory ticks.

In the US they've taken a different approach, setting their sights on the consumer FMCG market with byotrol 24. They are not resourced to finance competitive sales and marketing on this by themselves and so are seeking an investment partner, armed with real consumer data from the extended Target trial.

The coronavirus scare should, imo, give a boost to the prospects of finding a US investment partner on attractive terms. It may also open up the possibility of doing something similar with a hand sanitiser product in the US. It may push Solvay into accelerating whatever they have planned for Actizone (byotrol technology sold to Solvay, but with a retained royalty arrangement). Finally it may perhaps up their UK consumer profile, especially through the Boots deal where there is byotrol branding on the product - whether this is sufficient to justify a major push on UK consumer through either internal sales & marketing or seeking an investment partner here as well remains to be seen.

With luck, byotrol may now be in the right place at the right time: newly approved technology and labelling (and various "non-core" technologies ready for out-licensing) just as other companies struggle to address a more restrictive regulatory environment. And on consumer, a product with some particular selling points which may just catch a vastly-increased coronavirus-inspired demand for anti-virals.

Not that they don't deserve that luck in my opinion. The team under David Traynor has done exceptionally well to position the company here at this time, working within such a limited budget for many years. And at least on regulatory change, the company has been positioning for just such an outcome - you can read back through past reports to see that that is by design, not luck, although the Purrell news coinciding with the coronavirus scare is perhaps fortuitous in terms of increasing awareness of what byotrol has.

1gw
02/2/2020
13:21
Is the product too expensive to make it on the high street?

Is NHS type contracts the only way to success?

a.fewbob
02/2/2020
13:16
"only 3 in sales"

They also had a placing at 4p just over 2 yrs ago to raise upto £4.3m to FULLY resource an effective sales and marketing team...

Didn't they use the funds to fully resource their sales & marketing team then????



""We are delighted to have received such strong support from both existing and several significant new shareholders for this oversubscribed fundraising. The funding will allow the Board to capitalise on the substantial opportunities identified through our three core technologies. We will use these funds to fully resource an effective sales and marketing team in order to accelerate the Company's growth.""

sikhthetech
02/2/2020
13:14
Why is Byotrol product do expensive?

Is it due to production costs or something else?

a.fewbob
02/2/2020
12:51
Adding more sales resource is partly (if not mainly) what the acquisition of Medimark is about. If you look at the FY19 annual report you will see the statement:

"We did this for many years with approximately 18 employees - 7 in the laboratory, only 3 in sales - focussed on three areas, US surface care (regulated by the US EPA) EU surface care and EU and personal care (both regulated under the Biocidal Products Regulations)."

It's not easy to sell into the NHS with that sort of sales resource. The Medimark acquisition brings a capable sales team with a track record in selling into the professional segment. Medimark still adds only 13 "additional staff and management" according to the report, but on sales in particular it is a step change.

The great thing about removing the silo structure early with the completion of the earn-out is that Medimark sales staff can now be deployed wherever byotrol thinks is the best place for the current scenario, rather than being constrained to Medimark products.

1gw
02/2/2020
12:44
brownson,
good post...


Also Byot is in ONE Boots OWN brand product and Boots is just ONE retailer.... It's not as if Byot have cornered the market for hand santisers...

It's the retailers who are raking it in... even there Byotrol lost the Tesco contract only a few months ago so not exactly widely sold...


You can buy 4 of Boots other own brand 50ml hand santiser for 75p for the same price as 1 with Byot ingredients in it for £3.19...


Or even cheaper at Aldi 50ml hand santiser for 42p....so around 8 bottles of Aldi hand santiser for the same price as 1 with the Byot ingredients in it...

sikhthetech
02/2/2020
12:34
Exactly,

It’s super frustrating that a product like Byotrol can’t break into the NHS for use in general cleaning when we have so many resistant bug issues.

It seems insane.

a.fewbob
02/2/2020
11:29
The problem is that in the NHS we have to clean before and after every contact anyway so the fact byotrol lasts longer is irrelevant. Some of the infection control people have told me they fear that encouraging byotrol use will lead to people reducing cleaning of hands etc because they think they can get away with it. I think it would make sense to use it for cleaning floors though.Where I think it definitely has a place is on McDonalds touch screens which rapidly get colonised despite the undoubted efforts of the staff. The recently published study on bacterial growth on these screens made worrying reading
brownson
02/2/2020
01:12
Nice. First wave completed. Chart looking strong
letmepass
02/2/2020
01:11
Previous RNS says improved sales, margins and profits. It is all looking good. High of 82p. That would be nice
bob1995
02/2/2020
00:04
Marketing muscle-which is why corona virus helps.
cumnor
01/2/2020
23:42
But is there another product that keeps a surface protected for such a long time?

It seems to me that the product must be flawed!

Is there a problem with it that we just don’t know about?

I just find the whole thing frustrating.

a.fewbob
01/2/2020
23:17
Because other products are available.Guess that's why they lost the Tesco contract recently
saint in exile
01/2/2020
23:09
Thanks guys.

I can’t for the life of me understand why this isn’t the defacto sanitiser used across the NHS!

Why is this taking such a ludicrously long time to come good??

a.fewbob
01/2/2020
22:25
News will filter... Byotrol24 is scientifically proven to eliminate coronaviruses, noroviruses, flu and cold viruses, E. coli, salmonella, staph, strep, listeria, Pseudomonas aeruginosa and other germs. Watch the sakes. Start of a re rate here
letmepass
01/2/2020
17:25
What a great week TRMR, SLN and BYOT keep up the good work, much appreciated! Not so good for your troll
slicethepie
01/2/2020
13:58
A.Fewbob,

the main product in shops is Boots antiviral foam...available in 20ml & 50ml bottles..

Boots sell many different antibacterial santisers, so this is just 1 product.
There are many other shops selling many other antibacterial santisers...
They recently lost the contract with Tescos..

There are Byotrol products are also available online...


You'd have to be quick if you want Boots version online, as Kcowe is buying hundreds... lol


The hope is that the current coronavirus helps promote santisers etc and hopefully promotes Byotrol as a supplier with long lasting antiviral products to organisations (possibly via partnerships), here and abroad, rather than just end consumers..

People can use soap & water or any antibacterial santiser... so Byot is not the only effective way to kill Coronavirus...

sikhthetech
Chat Pages: Latest  318  317  316  315  314  313  312  311  310  309  308  307  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com